Tumor bearing experiments

SG Shanshan Gou
SW Shuai Wang
WL Wenwen Liu
GC Guanyu Chen
DZ Dongyang Zhang
JD Jiangfeng Du
ZY Zhongyi Yan
HW Hongfei Wang
WZ Wenjie Zhai
XS Xinghua Sui
YW Yahong Wu
YQ Yuanming Qi
YG Yanfeng Gao
ask Ask a question
Favorite

Female C57BL/6 mice were subcutaneously (s.c.) injected on the right back with 2 × 105 B16-OVA or B16 cells. On day 3 of the tumor cell inoculation, mice were randomly allocated into groups and vaccinated with 20 μg peptides or normal saline weekly for total of three times. Tumor volume was measured every other day. After five days of last immunization, mice were sacrificed. For IL-21 blocking experiment in vivo, mice were intraperitoneally (i.p.) injected 100 μg IL-21 neutralized antibody (FFA21) every eight days for total of twice.

Tumor tissue cell suspensions were stained with anti-mouse-CD45-FITC (30-F11), anti-mouse-CD3-PerCP-eFlour710 (17A2) and anti-mouse-CD8-APC (53-6.7) or Rat IgG2a-APC kappa Isotype Control (eBR2a) for tumor infiltrating CD8+ T cell analysis.

For intracellular cytokine staining (ICS), single cell suspension of splenocytes and draining lymph node (dLN) was stimulated with 10 μg/mL OVA257-264 peptide in the presence of protein transport inhibitor cocktail (eBioscience, San Diego, CA, US) for 6 h. Cells were then stained with surface markers CD3 and CD8 prior to fixation and permeabilization. Permeability cells were then stained with intracellular anti-mouse-IFN-γ-APC (XMG1.2), anti-mouse-Perforin-APC (eBioMAK-D), anti-mouse-Granzyme B-PerCP-eFlour710 (NGZB) antibody or isotype control antibody. Cells were collected and suspended in PBS containing 0.5% fetal bovine serum, incubated with the corresponding antibodies for 30 min on ice, washed once with PBS and analyzed by a FACS Calibur (Becton Dickinson, Franklin Lake, NJ, USA) flow cytometry.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A